Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases.
SORENTO CLINICAL TRIAL
The SORENTO study is seeking adult volunteers with advanced gastroenteropancreatic neuroendocrine tumours (GEP-NET). The study drug, CAM2029, is a long-acting investigational formulation of octreotide provided in either a ready-to-use syringe or pre-filled pen that can be administered at home by you or a caregiver. Learn more and find out if you could be part of this opportunity to test a potential new treatment option here.
The study drug, tests, examinations, and study-related medical care are provided at no cost to qualified study participants. Reimbursement for certain study-related expenses such as travel may be also available.
Criteria for Participation
To take part, you must:
Be 18 years of age or older
Have advanced (unresectable and/or metastatic) GEP-NET
Not have GEP-NET that has spread to the brain or central nervous system or progressed after previous treatment (refractory)
Not have been treated with long-acting SSAs for longer than 6 months
Other criteria will be reviewed to determine if you may participate in the study.
The study drug, tests, examinations, and study-related medical care are provided at no cost to qualified study participants. Reimbursement for certain study-related expenses such as travel may be available.
Do you have any questions? Contact Camurus at firstname.lastname@example.org.
This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by LACNETS. Talk to your medical team about your individual care and treatment.